Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib in pediatric and young adult patients with previously treated solid tumors
NL-OMON44717Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cobimetinib in Nonhematologic neoplasms, brain neoplasm, glioma and 11 more, sponsored by Roche. Primary endpoints: Incidence and nature of dose-limiting toxicities, Adverse events and 5 more. Planned start Mar 2016; status: withdrawn.
02
Drugs
cobimetinib
03
Conditions
Nonhematologic neoplasmsbrain neoplasmgliomadiffuse intrinsic pontine glioma (DIPG)rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NL-OMON44717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44717.